EW · 10-Q · 2026Q2 · Full report

Capital Return Program

Edwards Lifesciences Corp · 2026-08-04 · Importance 58 · Surprise 42 · Matches filing data

Edwards repurchased 6.9 million common shares for $558.7 million during the six months ended June 30, 2026. The repurchases included $500.0 million of accelerated share repurchase agreements executed during the period. The company had approximately $1.5 billion of remaining authorization at June 30, 2026. Financing cash outflows included $575.1 million of treasury-stock purchases, partly offset by $122.7 million of proceeds from stock plans.

Key facts

• During the six months ended June 30, 2026 Edwards repurchased 6.9 million shares at an aggregate cost of $558.7 million, including pursuant to a $500.0 million accelerated share repurchase executed during the period. source
• As of June 30, 2026, Edwards had remaining authority to purchase approximately $1.5 billion of common stock under the share repurchase program. source
• Net cash used in financing activities for the six months ended June 30, 2025 was $205.3 million, consisting primarily of purchases of treasury stock of $314.1 million, partially offset by proceeds from stock plans of $107.1 million. source
• Net cash used in financing activities was $451.5 million for the six months ended June 30, 2026, consisting primarily of purchases of treasury stock of $575.1 million, partially offset by proceeds from stock plans of $122.7 million. source

Impact estimates